EICHOR
● Completed
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Condition: Atopic Dermatitis · Sponsor: AbbVie
About this study
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (180)
| Alliance Dermatology and MOHs /ID# 200375 | Phoenix, Arizona, United States | — |
| Clear Dermatology & Aesthetics Center /ID# 201256 | Scottsdale, Arizona, United States | — |
| Bakersfield Derma & Skin Cance /ID# 200433 | Bakersfield, California, United States | — |
| First OC Dermatology /ID# 201910 | Fountain Valley, California, United States | — |
| California Allergy and Asthma Medical Group /ID# 200727 | Los Angeles, California, United States | — |
| Allergy & Asthma Associates of Southern California /ID# 200733 | Mission Viejo, California, United States | — |
| Dermatology Clinical Trials /ID# 205876 | Newport Beach, California, United States | — |
| UC Davis /ID# 203622 | Sacramento, California, United States | — |
| Synergy Dermatology /ID# 200842 | San Francisco, California, United States | — |
| San Luis Derm and Laser Clinic /ID# 200372 | San Luis Obispo, California, United States | — |
| Stanford University /ID# 200440 | Stanford, California, United States | — |
| Care Access Research - Walnut Creek /ID# 200940 | Walnut Creek, California, United States | — |
+ 168 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03569293